The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis

Nature Medicine

Volumn 14, Issue 7, 2008, Pages 748-755

  Neubert, Kirsten ^a   Meister, Silke ^a   Moser, Katrin ^b   Weisel, Florian ^c   Maseda, Damian ^a   Amann, Kerstin ^c   Wiethe, Carsten ^a   Winkler, Thomas H ^c   Kalden, Joachim R ^c   Manz, Rudolf A ^b   Voll, Reinhard E ^a,c  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b German Arthritis Research Center   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOUBLE STRANDED DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GLOMERULONEPHRITIS; IMMUNOGLOBULIN PRODUCTION; IMMUNOHISTOCHEMISTRY; LUPUS LIKE SYNDROME; MOUSE; MOUSE STRAIN; MYELOMA CELL; NEPHRITIS; NONHUMAN; PLASMA CELL; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN SYNTHESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT DURATION; TREATMENT RESPONSE;

ANIMALS; BORONIC ACIDS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; MICE, INBRED BALB C; MICE, INBRED MRL LPR; MICE, INBRED NZB; MODELS, IMMUNOLOGICAL; NEPHRITIS; OVALBUMIN; PLASMA CELLS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; TIME FACTORS;

MUS;

EID: 46749088320     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1763     Document Type: Article

References (49)

1. Lipsky, P.E. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat. Immunol. 2, 764-766 (2001).
2. Mills, J.A. Systemic lupus erythematosus. N. Engl. J. Med. 330, 1871-1879 (1994).
3. Manz, R.A. & Radbruch, A. Plasma cells for a lifetime? Eur. J. Immunol. 32, 923-927 (2002).
4. Miller, J.J., III & Cole, L.J. Resistance of long-lived lymphocytes and plasma cells in rat lymph nodes to treatment with prednisone, cyclophosphamide, 6 mercaptopurine and actinomycin D. J. Exp. Med. 126, 109-125 (1967).
5. Slifka, M.K. & Ahmed, R. Long-lived plasma cells: a mechanism for maintaining persistent antibody production. Curr. Opin. Immunol. 10, 252-258 (1998).
6. Ang, H.A., Apperley, J.F. & Ward, K.N. Persistence of antibody to human parvovirus B19 after allogeneic bone marrow transplantation: role of prior recipient immunity. Blood 89, 4646-4651 (1997).
7. van Tol, M.J. et al. The origin of IgG production and homogeneous IgG components after allogeneic bone marrow transplantation. Blood 87, 818-826 (1996).
8. Theofilopoulos, A.N. & Dixon, F.J. Murine models of systemic lupus erythematosus. Adv. Immunol. 37, 269-390 (1985).
9. Hoyer, B.F. et al. Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. J. Exp. Med. 199, 1577-1584 (2004).
10. Manz, R.A., Hauser, A.E., Hiepe, F. & Radbruch, A. Maintenance of serum antibody levels. Annu. Rev. Immunol. 23, 367-386 (2005).
11. Adams, J. The proteasome: a suitable antineoplastic target. Nat. Rev. Cancer 4, 349-360 (2004).
12. Hideshima, T., Richardson, P.G. & Anderson, K.C. Targeting proteasome inhibition in hematologic malignancies. Rev. Clin. Exp. Hematol. 7, 191-204 (2003).
13. Rajkumar, S.V., Richardson, P.G., Hideshima, T. & Anderson, K.C. Proteasome inhibition as a novel therapeutic target in human cancer. J. Clin. Oncol. 23, 630-639 (2005).
14. Meister, S. et al. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res. 67, 1783-1792 (2007).
15. Obeng, E.A. et al. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 107, 4907-4916 (2006).
16. Hibi, T. & Dosch, H.M. Limiting dilution analysis of the B cell compartment in human bone marrow. Eur. J. Immunol. 16, 139-145 (1986).
17. Lefkowith, J.B. & Gilkeson, G.S. Nephritogenic autoantibodies in lupus: current concepts and continuing controversies. Arthritis Rheum. 39, 894-903 (1996).
18. Hahn, B.H. Antibodies to DNA. N. Engl. J. Med. 338, 1359-1368 (1998).
19. Manz, R.A., Thiel, A. & Radbruch, A. Lifetime of plasma cells in the bone marrow. Nature 388, 133-134 (1997).
20. Radbruch, A. et al. Competence and competition: the challenge pf becoming a long-lived plasma cell. Nat. Rev. Immunol. 6, 741-750 (2006).
21. Nencioni, A. et al. Proteasome inhibitor bortezomib modulates TLR4-induced dendritic cell activation. Blood 108, 551-558 (2006).
22. Straube, C. et al. Bortezomib significantly impairs the immunostimulatory capacity of human myeloid blood dendritic cells. Leukemia 21, 1464-1471 (2007).
23. Oyadomari, S. & Mori, M. Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ. 11, 381-389 (2004).
24. Moran, S.T. et al. Synergism between NF-κB1/p50 and Notch2 during the development of marginal zone B lymphocytes. J. Immunol. 179, 195-200 (2007).
25. Sasaki, Y. et al. Canonical NF-κB activity, dispensable for B cell development, replaces BAFF-receptor signals and promotes B cell proliferation upon activation. Immunity 24, 729-739 (2006).
26. Maseda, D., Meister, S., Neubert, K., Herrmann, M. & Voll, R.E. Proteasome inhibition drastically but reversibly impairs murine lymphocyte development. Cell Death Differ. 15, 600-612 (2008).
27. Schubert, U. et al. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature 404, 770-774 (2000).
28. Gass, J.N., Gifford, N.M. & Brewer, J.W. Activation of an unfolded protein response during differentiation of antibody-secreting B cells. J. Biol. Chem. 277, 49047-49054 (2002).
29. Iwakoshi, N.N. et al. Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1. Nat. Immunol. 4, 321-329 (2003).
30. Kaufman, R.J. Stress signaling from the lumen of the endoplasmic reticulum: coordination of gene transcriptional and translational controls. Genes Dev. 13, 1211-1233 (1999).
31. Patil, C. & Walter, P. Intracellular signaling from the endoplasmic reticulum to the nucleus: the unfolded protein response in yeast and mammals. Curr. Opin. Cell Biol. 13, 349-355 (2001).
32. Reimold, A.M. et al. Plasma cell differentiation requires the transcription factor XBP-1. Nature 412, 300-307 (2001).
33. van Anken, E. et al. Sequential waves of functionally related proteins are expressed when B cells prepare for antibody secretion. Immunity 18, 243-253 (2003).
34. Wiertz, E.J. et al. Sec61-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction. Nature 384, 432-438 (1996).
35. Kim, R., Emi, M., Tanabe, K. & Murakami, S. Role of the unfolded protein response in cell death. Apoptosis 11, 5-13 (2006).
36. Nawrocki, S.T. et al. Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. Cancer Res. 65, 11510-11519 (2005).
37. Nawrocki, S.T. et al. Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. Cancer Res. 65, 11658-11666 (2005).
38. Schaumann, D.H., Tuischer, J., Ebell, W., Manz, R.A. & Lauster, R. VCAM-1-positive stromal cells from human bone marrow producing cytokines for B lineage progenitors and for plasma cells: SDF-1, flt3L and BAFF. Mol. Immunol. 44, 1606-1612 (2007).
39. Tokoyoda, K., Egawa, T., Sugiyama, T., Choi, B.I. & Nagasawa, T. Cellular niches controlling B lymphocyte behavior within bone marrow during development. Immunity 20, 707-718 (2004).
40. Klinman, D.M. & Steinberg, A.D. Inquiry into murine and human lupus. Immunol. Rev. 144, 157-193 (1995).
41. Winfield, J.B., Faiferman, I. & Koffler, D. Avidity of anti-DNA antibodies in serum and IgG glomerular eluates from patients with systemic lupus erythematosus. Association of high avidity antinative DNA antibody with glomerulonephritis. J. Clin. Invest. 59, 90-96 (1977).
42. Cambridge, G. et al. B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum. 54, 3612-3622 (2006).
43. Sfikakis, P.P. et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum. 52, 501-513 (2005).
44. Leandro, M.J., Edwards, J.C., Cambridge, G., Ehrenstein, M.R. & Isenberg, D.A. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 46, 2673-2677 (2002).
45. Emery, P. et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 54, 1390-1400 (2006).
46. Looney, R.J. et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum. 50, 2580-2589 (2004).
47. Medina, F., Segundo, C., Campos-Caro, A., Gonzalez-Garcia, I. & Brieva, J.A. The heterogeneity shown by human plasma cells from tonsil, blood, and bone marrow reveals graded stages of increasing maturity, but local profiles of adhesion molecule expression. Blood 99, 2154-2161 (2002).
48. Benner, R., Van Oudenaren, A. & Koch, G. Induction of antibody formation in mouse bone marrow. in Immunological Methods Vol. II (eds. Pernis, B. & Lefkovits, I.) 247-262 (Academic Press, New York, 1981).
49. Wellmann, U., Letz, M., Schneider, A., Amann, K. & Winkler, T.H. An Ig μ-heavy chain transgene inhibits systemic lupus erythematosus immunopathology in autoimmune (NZB x NZW)F1 mice. Int. Immunol. 13, 1461-1469 (2001).